Mysm1 epigenetically regulates the immunomodulatory function of adipose-derived stem cells in part by targeting miR-150

Yu-Han Wang1 | Xiao-Hui Huang1,2 | Yan-Mei Yang1,3 | Youdi He4 | Xiao-Hui Dong1 | Hui-Xin Yang1,3 | Lei Zhang5 | Yan Wang1 | Jin Zhou1 | Changyong Wang1 | Xiao-Xia Jiang1,2

1Department of Neural Engineering and Biological Interdisciplinary Studies, Institute of Military Cognition and Brain Sciences, Academy of Military Medical Sciences, Beijing, P.R. China
2Anhui Medical University, Hefei, Anhui, China
3Department of Stomatology, Chinese PLA General Hospital, Beijing, P.R. China
4Department of Neurology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
5College of Agroforestry Engineering and Planning, Tongren University, Tongren, Guizhou, China

Abstract

Adipose-derived stem cells (ASCs) are highly attractive for cell-based therapies in tissue repair and regeneration because they have multilineage differentiation capacity and are immunosuppressive. However, the detailed epigenetic mechanisms of their immunoregulatory capacity are not fully defined. In this study, we found that Mysm1 was induced in ASCs treated with inflammatory cytokines. Adipose-derived stem cells with Mysm1 knockdown exhibited attenuated immunosuppressive capacity, evidenced by less inhibition of T cell proliferation, more pro-inflammatory factor secretion and less nitric oxide (NO) production in vitro. Mysm1-deficient ASCs exacerbated inflammatory bowel diseases but inhibited tumour growth in vivo. Mysm1-deficient ASCs also showed depressed miR-150 expression. When transduced with Mysm1 overexpression lentivirus, ASCs exhibited enhanced miR-150 expression. Furthermore, Mysm1-deficient cells transduced with lentivirus containing miR-150 mimics produced less pro-inflammatory factors and more NO. Our study reveals a new role of Mysm1 in regulating the immunomodulatory activities of ASCs by targeting miR-150. These novel insights into the mechanisms through which ASCs regulate immune reactions may lead to better clinical utility of these cells.

Keywords

adipose-derived stem cells, miR-150, Mysm1, nitric oxide
Adipose-derived stem cells (ASCs) are similar to bone marrow-derived stem cells (BMSCs) in their ability to differentiate into multiple cell types, including bone, cartilage, adipocytes and neurons.\(^{1,2}\) Additionally, ASCs are immunosuppressive and express similar surface markers to BMSCs.\(^{6}\) Unlike BMSCs, clinically applicable numbers of ASCs can easily be obtained from adipose tissue collected through minimally invasive procedures such as lipoplasty.\(^{7}\) Due to these properties, ASCs are appealing for use in cell-based therapies for tissue repair and regeneration.

Allogeneic ASCs are immune privileged and have immunomodulatory capabilities. In vitro, ASCs inhibit the proliferation and function of activated immune cells through cell-cell binding and paracrine signalling.\(^{8}\) In vivo, ASCs have demonstrated therapeutic potential in numerous immune-mediated conditions in both pre-clinical and clinical studies, including graft-vs-host disease (GvHD) and chronic inflammatory autoimmune diseases.\(^{9,10}\) There are several possible mechanisms through which ASCs function to suppress immunity. A series of factors and molecules produced by ASCs, such as prostaglandin (PG) E2,\(^{12}\) transforming growth factor-β (TGF-β),\(^{14}\) and interleukin (IL)-10,\(^{14,15}\) have been shown to be critical for their immunoregulatory functions. While many of these factors have been well characterized, much remains unknown about the immunomodulatory function and therapeutic efficacy of ASCs.

Mysm1, a histone deubiquitinase, mediates the deubiquitination of lysine 119 (K119) of histone H2A,\(^{16}\) and removes K63 polyubiquitins attached to TRAF3 and TRAF6.\(^{17}\) We and several other groups have previously demonstrated that Mysm1 plays a crucial role in stem cell maintenance and immune cell development and function.\(^{18,19}\) Mysm1 can control essential lineage-specific developmental regulators and miRNA expression at a transcriptional level, and it regulates the p53 stress response pathway in a cell-specific manner.\(^{25,26}\) Despite these observations, knowledge of the biological functions of Mysm1 remains incomplete and its role in ASC immunoregulatory function has not been investigated.

In the present study, we demonstrate that Mysm1-deficient ASCs showed attenuated inhibition of T cell proliferation in vitro, while exacerbating inflammatory bowel diseases and inhibiting tumour growth in vivo. Further mechanistic studies revealed that Mysm1 regulates the immunomodulatory capacity of ASCs by targeting miR-150 expression. Taken together, our data reveal a novel role of Mysm1 in regulating the immunomodulatory activities of ASCs.

2 | MATERIALS AND METHODS

2.1 | Animals

Groups of 3-4-week-old and 8-12-week-old C57BL/6 mice were obtained from the Laboratory Animal Center of the Academy of Military Medical Sciences of China (Beijing). Mysm1-deficient (KO) mice were generated as described previously.\(^{18}\) In all experiments, age- and sex-matched wild type (WT) littermates were used for controls. Mice were maintained in a pathogen-free barrier facility. All animal experiments were performed according to the ‘Guide for the Care and Use of Laboratory Animals’ approved by the Beijing Institute of Military Cognition and Brain Sciences. The institutional Ethics Review Committee for Animal Experimentation approved all experimental protocols.
2.5 | Quantitative RT-PCR

Total RNA was extracted with TRizol (Sigma-Aldrich) and reverse transcribed into cDNA with a reverse transcriptase kit (Toyobo, Osaka, Japan). cDNA was used as a template in quantitative PCR with Synergy Brands Synergy Brands (SYBR) Green (Toyobo) to determine specific gene expression. Total mRNA was normalized to endogenous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Primer pairs were as follows: Mysm1: GATGCAGAAGCAGCATACCA (forward) and CCTCCACAGACAAATGCTCA (reverse); inducible nitric oxide synthases (iNOS): CAGCTGGGCTGTACAAACCTT (forward) and CATTGGAAGTGAAGCGTTTCCG (reverse); IL-10: CCAAGCCTTATCGGAAATGA (forward) and TCTCACCCAGGGAATTCAAA (reverse); interferon-gamma (IFN-γ): GGTCACAAACCCACAGGT, (forward) and GACCTCTTTCGGTTCCTCT (reverse); IL-1β: CATTAGACCA CTGCACTACGG (forward) and GTTCTCCTTGTACAAAGCTCAT (reverse); IL-6: AGATAAGCTGGAGTCACAGAAGGAG (forward) and CCAGCTGGAGTTTTGGTTATCT (reverse); and GAPDH: ACAATGAAATACGGCTACAG (forward) and GTCCAGGGTCTTACTC (reverse).

2.6 | Lentivirus production and transduction

Recombinant lentiviral vectors containing Mysm1 or miR-150 were purchased from Genechem (Shanghai, China). Adipose-derived stem cells or C3H/10T1/2 cells were transduced as described in our previous publications.18,25

2.7 | Chromatin immunoprecipitation

Chromatin was immunoprecipitated according to the manufacturer’s instructions (Cell Signaling Technology, Danvers, MA). Briefly, cell suspensions were crosslinked with 1% (vol/vol) formaldehyde. Chromatin was isolated, digested by mung bean nuclease (MNase), sheared by sonication and immunoprecipitated with antibodies. Immunoprecipitated DNA was washed and eluted according to the manufacturer’s instructions. Eluted DNA and sheared input material was analyzed by quantitative PCR. Primer pairs for miR-150 promoter regions were as follows: miR-150 prom 9: AGGTATCTCATTGAGACA (forward) and CAGGTTTCTCTGTGTAACA (reverse); miR-150 prom 10: TCTTGCAAAAAACAACACCA (forward) and TGGAGGCCTTCTTACTC (reverse).

2.8 | Western blot

Cells were lysed with lysis buffer and protein samples were separated on 12% SDS-polyacrylamide gel, and then the proteins were transferred to 0.45 μm polyvinylidene fluoride blotting membranes. The membrane was blocked in 5% non-fat dry milk for 1 hour, then were probed with primary antibodies against the proteins of interest in blocking solution overnight at 4°C, washed and then incubated in horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 hour at room temperature. Finally, enhanced chemiluminescence substrate (Thermo Fisher, Waltham, MA) was added to the membranes and the proteins were assayed according to manufacturer instructions. Antibodies against GAPDH, Mysm1 were purchased from Cell Signaling Technology, Inc.

2.9 | Induction of acute colitis

Acute colitis was induced in C57BL/6 mice by administering 3% dextran sodium sulphate (DSS; molecular weight 40 000 Da; Sigma-Aldrich) from day 0 to day 7 in drinking water. On day 1, WT and Mysm1 KO ASCs were injected intraperitoneally in DSS-treated animals. Colitis severity was assessed daily by scoring (0-4) the clinical disease activity through evaluation of stool consistency, presence of faecal blood and weight loss. Mice with acute colitis were euthanized on day 8. The entire colon was removed from the caecum to the anus, and colon length and weight were measured as indirect inflammation markers. The macroscopic colonic damage score was assessed based on the grade of tissue adhesion, presence of ulceration and wall thickness.

2.10 | Mouse melanoma model

B16-F0 murine melanoma cells (CRL-6322; ATCC, Manassas, VA) were expanded in complete DMEM in vitro. Each mouse was injected with 5 × 10^5 B16-F0 cells in 100 μL PBS intramuscularly on the left thigh, with or without co-injection of WT or Mysm1-deficient ASCs (1 × 10^6 per mouse). Mice were observed daily and euthanized when tumors began to significantly affect mobility. Melanoma tumors were then excised and weighed. Each experimental group included at least five mice.

2.11 | Statistical Analysis

All data were analyzed with Prism 5.0 software (GraphPad Software, San Diego, CA) and are presented as the means ± SDs. Statistical significance was assessed by unpaired two-tailed Student`s t tests (*P < 0.05; **P < 0.01).

3 | RESULTS

3.1 | Inflammatory cytokines induce Mysm1 expression in ASCs

Mysm1 plays essential roles in stem cell maintenance and immune cell function. Mysm1 activity has been reported in the nucleus16 and cytoplasm17 with cell-specific properties. Adipose-derived stem cells are stem cells with immunomodulatory capacities. To investigate the effect of Mysm1 on ASCs, the expression levels of Mysm1 in ASCs was examined. Immunofluorescence staining (Figure 1A) showed that under basal conditions, Mysm1 was localized in both nucleus and cytoplasm of ASCs, whereas adherent cells isolated from murine bone expressed Mysm1 in the cytoplasm. To further determine the effect of Mysm1 on the immunomodulatory...
function of ASCs, Mysm1 expression in ASCs treated with inflammatory cytokines was analyzed. As shown in Figure 1B, Mysm1 mRNA levels increased in a dose-dependent manner with tumour necrosis factor-α (TNF-α) plus IFNγ for 12 h at different concentrations and then collected in TRIzol. Mysm1 mRNA levels were determined with quantitative RT-PCR. C, Adipose-derived stem cells were treated with 10 ng/mL TNF-α and 10 ng/mL IFNγ for 30 min, 60 min and 24 h, then Mysm1 protein levels were determined by Western blot. **P < 0.01

**FIGURE 1** Inflammatory cytokines induce Mysm1 expression. A, Immunofluorescence analysis of Mysm1 expression in murine-derived adipose-derived stem cells (ASCs) and bone cells. Scale bars: 50 µm. B, Adipose-derived stem cells were treated with tumour necrosis factor-α (TNF-α) plus IFNγ for 12 h at different concentrations and then collected in TRIzol. Mysm1 mRNA levels were determined with quantitative RT-PCR. C, Adipose-derived stem cells were treated with 10 ng/mL TNF-α and 10 ng/mL IFNγ for 30 min, 60 min and 24 h, then Mysm1 protein levels were determined by Western blot. **P < 0.01

3.2 | Mysm1 knockdown attenuates the immunosuppressive capacity of ASCs

To test the involvement of Mysm1 in ASC immunomodulatory activity, ASCs from Mysm1 KO and WT mice were isolated. The deficient expression of Mysm1 in KO ASCs was confirmed by quantitative RT-PCR and Western blot analysis (Figure 2A). Surface markers and cell cycle were examined by flow cytometry and no significant differences were observed between cultures of KO ASCs and their WT counterparts (data not shown). Next, T cell proliferation was used as an immune response model, in which a reduction of CFSE intensity was measured to determine T cell proliferation (Figure 2B). As shown in Figure 2C, both WT and KO ASCs directly inhibited T cell proliferation in a dose-dependent manner, but KO ASCs were less efficient, evidenced by a lesser reduction in CFSE intensity. To better characterize the function of Mysm1, inflammatory cytokine expression in WT and KO ASCs was analyzed. Quantitative RT-PCR data (Figure 2D) revealed that under basal culture condition and compared to WT counterparts, KO ASCs had higher expression of the inflammatory genes IFNγ and IL-1β, and lower expression of the anti-inflammatory gene IL-10 and much less iNOS. Additionally, no matter without or with TNF-α and IFNγ stimulation, KO ASCs exhibited significantly lower nitric oxide (NO) production (Figure 2E).

3.3 | KO ASCs exacerbated dextran sulfate sodium-induced colitis but suppressed tumour growth in vivo

Next, the physiological function of KO ASCs was investigated in an experimental model of acute colitis induced by oral dextran sulphate sodium (DSS) administration. After 8 days, mice receiving an oral administration of 3% DSS exhibited a significant increase in the disease activity index, characterized by acute colitis, bloody diarrhoea and sustained weight loss (Figure 3A-E). Subsequent treatment with WT ASCs increased survival rate, ameliorated weight loss and improved the disease severity. Conversely, treatment with KO ASCs exacerbated DSS-induced colitis, leading to increased disease severity characterized by further weight loss, diarrhoea and bloody stools and signs of colon damage (Figure 3B-E). Previous studies have shown that mesenchymal stem cells (MSCs) with attenuated immunosuppressive capacities can inhibit tumour growth.27,28 Compared to WT counterparts, KO ASCs are less immunosuppressive both in vitro and in vivo. Thus a murine
melanoma model was used to determine the effect of KO ASCs on tumour growth in vivo. B16-F0 melanoma cells were co-administered with WT ASCs or KO ASCs and the resultant tumours were weighed after 13 days. In contrast to WT ASCs that promoted tumour growth, infusion of KO ASCs was found to significantly inhibit tumour growth (Figure 4A, B). Therefore, modulation of ASCs could provide a novel strategy for tumour immunotherapy.

### 3.4 | Mysm1 epigenetically regulates miR-150 expression in ASCs

miR-150 is an important regulator of differentiation and activation of immune cells. Our previous studies have demonstrated that Mysm1 regulates miR-150 expression and is involved in B1a cell proliferation.29 Here, the expression of miR-150 in KO ASCs or an Mysm1 knockdown murine MSC line was significantly lower than that in their WT counterparts (Figure 5A). The expression of miR-155-5p and miR-155-3p was comparable in WT and KO ASCs, although miR-155 has been reported to regulate immune modulatory properties of MSCs.29 We therefore focused on miR-150 for further studies. To investigate how Mysm1 might regulate miR-150 in ASCs, we first transduced KO ASCs with Mysm1-expressing lentivirus (LV-Mysm1). As shown in Figure 5B, most cells were green fluorescent protein (GFP) positive, indicating high transduction efficiency. Quantitative RT-PCR data confirmed the over expression of Mysm1. miR-150 level was also examined in KO ASCs with Mysm1 overexpression compared to that of control transduced counterparts (Figure 5B). Next,
**FIGURE 3** Mysm1-deficient adipose-derived stem cells (ASCs) exacerbated dextran sodium sulphate (DSS)-induced colitis. A, Schematic representation of mouse colitis experiments. Mice received 3% DSS in drinking water from day 0 to day 8. Adipose-derived stem cells (1 × 10^6/mouse) were infused intraperitoneally on day 1. Weight loss (B) and disease activity scores (C) were observed daily. Colon weight (D) and colon length (E) were measured on day 8. Control mice received no DSS in drinking water. n = 6 mice/group. *DSS + WT ASCs vs DSS + KO ASCs, *P < 0.05 and **P < 0.01

**FIGURE 4** Mysm1-deficient adipose-derived stem cells (ASCs) suppress tumour growth in vivo. On day 1, 5 × 10^5 B16-F0 cells were injected subcutaneously to the back of C57BL/6 mice, with or without co-injection of WT or KO ASCs (1 × 10^6 cells per mouse). Seven days later, tumour size was measured daily (A). On day 13, mice were euthanized and the tumours were weighed (B, top), and pictures of the representative tumour of each group were taken under a microscope (B, bottom). Each treatment group included five mice, and data are representative of three independent experiments. Wild type (WT) ASCs vs KO ASCs, *P < 0.05 and **P < 0.01
we set out to examine whether Mysm1 regulates the transcription of miR-150 and investigated the association of Mysm1 with the pri-miR-150 promoter locus by using chromatin immunoprecipitation (ChIP) assays. PCR primer pairs encompassing the pri-miR-150 promoter region were used. Immunoprecipitation with the Mysm1-specific antibody enriched the sequences located at pri-miR-150 promoter in WT ASCs, but not in KO ASCs (Figure 5C), which might account for the lower expression of pri-miR-150 in KO ASCs (Figure 5D).

3.5 miR-150 regulates iNOS expression

To further investigate the role of Mysm1 in controlling miR-150 expression as part of the immunomodulatory function of ASCs, we performed a rescue assay in KO ASCs with a lentivirus vector expressing miR-150. GFP expression indicated high transduction efficiency (data not shown) and quantitative RT-PCR data confirmed the overexpression of miR-150 in KO ASCs (Figure 6A). Higher expression of iNOS was found in KO ASCs with miR-150 overexpression (Figure 6B). And when stimulated with TNF-α and IFNγ, KO ASCs transduced with miR-150 mimics produced much more NO (Figure 6C). Inducible nitric oxide synthases is essential for MSC-induced immunosuppression. Similarly, the murine MSC cell line C3H/10T1/2 transduced with miR-150 mimics (Figure 6D) also showed higher level of iNOS (Figure 6E), and exhibited more NO production (Figure 6F) with TNF-α and IFNγ treatment. However, miR-150 transduction did not affect the expression of surface
markers programmed cell death 1 ligand 1 (PD-L1), vascular cell adhesion molecule 1 (VCAM-1) or intercellular adhesion molecule-1 (ICAM-1) (data not shown). These data indicate that Mysm1 epigenetically regulates miR-150, which leads to enhanced iNOS expression and thus more NO production (Figure 7).

4 | DISCUSSION

In addition to their use in tissue repair and regenerative medicine, ASCs have been utilized in treating immune disorders due to their immunomodulatory properties.9,10 A series of factors are known to be critical for ASC immunoregulation. The present study provides the first report on alteration of ASC immunomodulatory function by the epigenetic molecule Mysm1, which regulates miR-150.

Previous studies have shown that Mysm1 controls the development of several hematopoietic lineages, including B,18 T,24 natural killer,20 and dendritic cells.31 This is attributed to the function of Mysm1 in the direct regulation of lineage-specific transcription factors. In addition to localizing in the nucleus and being a key component of epigenetic signalling machinery, Mysm1 can interact with and inactivate TRAF3 and TRAF6, and thus inhibit PRR pathways in the cytoplasm.17 Similar to MSCs, the immunosuppressive function of ASCs is elicited by proinflammatory cytokines. In the present study, we show that Mysm1 is induced by inflammatory cytokines in ASCs similar to in macrophages. However, while localized to the cytoplasm of macrophages,17 Mysm1 is located in both the nuclei and cytoplasm of ASCs, and epigenetically regulates the expression of miR-150. Despite these novel findings, more studies are required to understand the activity of Mysm1 in the cytoplasm of ASCs.

Mesenchymal stem cell-based immune regulation mainly occurs through paracrine effects by the production of soluble factors, including NO, prostaglandin E2 (PGE2) indoleamine 2,3-dioxygenase (IDO), but may also occur through direct cell-cell contact. Similar to MSCs, the immunosuppressive capacity of ASCs by reducing iNOS expression. In the present study, miR-155 was also induced in ASCs treated with inflammatory cytokines; however, the expression level of miR-155 was unchanged for WT and KO ASCs. In contrast to miR-155, the expression of miR-150 in KO ASCs was significantly lower than that in WT ASCs. In addition, the expression of miR-150 is also decreased in human placental derived MSCs with Mysm1 knockdown and in murine MSC C3H/10T1/2 cells with Mysm1 knockdown (data not shown). Furthermore, we showed that Mysm1 targets the promoter region of pri-miR-150, and over-expression of Mysm1 in ASCs leads to significant up-regulation of miR-150. NO production is catalyzed by NO synthases and NO is essential for the immunosuppressive capacity of ASCs.32,40 Compared with those in WT counterparts, the

**P < 0.01
supernatant nitrate concentration and iNOS mRNA expression were significantly lower in KO ASCs. When KO ASCs or murine MSC C3H/10T1/2 cells were transduced with miR-150 mimics, NO production was dramatically increased.

5 | CONCLUSIONS

This study reveals that Mysm1 regulates the immunosuppressive capacity of ASCs by targeting miR-150, and thus uncovers a previously undescribed role of Mysm1 in regulating the immunomodulatory activities of ASCs. These novel insights into the mechanisms through which ASCs regulate immune reactions may help to improve the clinical utility of these cells in many inflammation related diseases.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

All experimental animal protocols for this study are in accordance with the national guidelines for the use of animals in scientific research. Additional approval was granted by the Animal Care and Use Committee of the Academy of Military Medical Sciences.

ACKNOWLEDGEMENTS

The authors sincerely thank Lindsey Jones and Dr. Andrew Woodham for their critical review of this manuscript. This study was financially supported by grant from Beijing Natural Science Foundation (No.7162142 to XXJ), Program of International Scientific and Technological Cooperation and Exchanges of China (No. 31320103914 to CW), National Key Research and Development Program (No. 2016YFC1101303 to CW, No. 2017YFA0106100 to JZ), National Natural Science Foundation of China (No. 81771998 to XXJ, No. 81622027 to JZ), and Basic Research Project of Guizhou Science and Technology Department (20171188 to LZ).

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

AUTHORS’ CONTRIBUTIONS

XXJ and CW conceived and designed the experiments. YHW, XHH, YMY, YH, XHD, HXY, LZ andYW performed the experiments. YHW, XHH, YMY, YH, XHD, HXY, LZ, YW, JZ, XXJ and CW analyzed experimental data. XXJ and CW wrote the manuscript. All authors read and approved the manuscript.

ORCID

Xiao-Xia Jiang https://orcid.org/0000-0003-1401-9653

REFERENCE

1. Aksu AE, Rubin JP, Dudas JR, Marra KG. Role of gender and anatomical region on induction of osteogenic differentiation of human adipose-derived stem cells. Ann Plast Surg. 2008;60:306-322.
2. Xie X, Wang Y, Zhao C, et al. Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration. Biomaterials. 2012;33:7008-7018.
3. Merceron C, Portron S, Masson M, et al. The effect of two- and three-dimensional cell culture on the chondrogenic potential of human adipose-derived mesenchymal stem cells after subcutaneous transplantation with an injectable hydrogel. Cell Transplant. 2011;20:1575-1588.
4. Wosnitza M, Hemmrich K, Groger A, Gräber S, Pallua N. Plasticity of human adipose stem cells to perform adipogenic and endothelial differentiation. Differentiation. 2007;75:12-23.
5. Bourin P, Bunnell BA, Castella L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15:641-648.
6. Kokai L, Marra K, Rubin JP. Adipose stem cells: biology and clinical applications for tissue repair and regeneration. Transl Res. 2014;163:399-408.
7. Lee RH, Kim B, Choi I, et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem. 2004;14:311-324.
8. McIntosh KR. Evaluation of cellular and humoral immune responses to allogeneic adipose-derived stem/stromal cells. Methods Mol Biol. 2011;702:133-150.
9. Yañez R, Lamana ML, García-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24:2582-2591.
10. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. *Gastroenterology*. 2009;136:978-989.

11. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. *Arthritis Rheum*. 2009;60:1006-1019.

12. McIntosh KR, Frazier T, Rowan BG, Gimble JM. Evolution and future prospects of adipose-derived immunomodulatory cell therapeutics. *Exp Rev Clin Immunol*. 2013;9:175-184.

13. Cui L, Yin S, Liu W, Li N, Zhang W, Cao Y. Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. *Tissue Eng*. 2007;13:1185-1195.

14. Li MQ, Flavell RA. Contextual regulation of inflammation: a secret by transforming growth factor-b and interleukin-10. *Immunity*. 2008;28:468-476.

15. Gonzalez-Rey E, Anderson P, Gonzalez MA, Rico L, Buscher D, Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. *Gut*. 2009;58:929-939.

16. Zhu P, Zhou W, Wang J, et al. A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. *Mol Cell*. 2007;7:609-621.

17. Panda S, Nilsson JA, Gekara NO. Deubiquitinase MYSM1 regulates innate immunity through inactivation of TRAF3 and TRAF6 complexes. *Immunity*. 2015;43:647-659.

18. Jiang X-X, Nguyen Q, Chou Y, et al. Control of B cell development by the histone H2A deubiquitinase MYSM1. *Immunity*. 2011;35(6):883-896.

19. Li P, Yang Y-M, Sanchez S, et al. Deubiquitinase MYSM1 is essential for normal bone formation and mesenchymal stem cell differentiation. *Sci Rep*. 2016;6:22211.

20. Alsultan A, Shamseldin HE, Osman ME, Aljafari M, Alkurya FS. MYSM1 is mutated in a family with transient transfusion-dependent anemia, mild thrombocytopenia, and low NK- and B-cell counts. *Blood*. 2013;122:3842-3845.

21. Le Guen T, Touzet F, Andre-Schmutz I, et al. An in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphopoiesis differentiation. *J Allergy Clin Immunol*. 2015;136(6):e1619-e1626.e1-5.

22. Nijnik A, Clare S, Hale C, et al. The critical role of histone H2A-deubiquitinase Mysm1 in hematopoiesis and lymphopoiesis differentiation. *Blood*. 2012;119:1370-1379.

23. Wang T, Nandakumar V, Jiang X-X, et al. The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation. *Blood*. 2013;122:2812-2822.

24. Gatzka M, Tasdogan A, Hainzl A, et al. Interplay of H2A deubiquitinase 2A-DUB/Mysm1 and the p19(ARF)/p53 axis in hematopoiesis, early T-cell development and tissue differentiation. *Cell Death Differ*. 2015;22:1451-1462.

25. Jiang XX, Liu Y, Li H, et al. MYSM1/miR-150/FLT3 inhibits B1a cell proliferation. *Oncotarget*. 2016;7(42):68086-68096.

26. Belle Ji, Petrov JC, Langlais D, et al. Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance. *Cell Death Differ*. 2016;23:759-775.

27. Li W, Ren G, Huang Y, et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. *Cell Death Differ*. 2012;19:1505-1513.

28. Dang R-J, Yang Y-M, Zhang L, et al. A20 plays a critical role in the immunoregulatory function of mesenchymal stem cells. *J Cell Mol Med*. 2016;20(8):1550-1560.

29. Xu C, Ren G, Cao G, et al. miR-155 regulates immune modulatory properties of mesenchymal stem cells by targeting TAK1-binding protein 2. *J Biol Chem*. 2013;288(16):11074-11079.

30. Nandakumar V, Chou YC, Yang XF, Chen SY. Epigenetic control of natural killer cell maturation by histone H2A deubiquitinase, MYSM1. *Proc Natl Acad Sci USA*. 2013;110:E3927-E3936.

31. Won H, Nandakumar V, Yates P, et al. Epigenetic control of dendritic cell development and fate determination of common myeloid progenitor by Mysm1. *Blood*. 2014;124:2647-2656.

32. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. *Cell Stem Cell*. 2008;2:141-150.

33. Németh K, Leelahavanichkul A, Yuen P, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med*. 2009;15:42-49.

34. Duffy MM, Pindjakova J, Hanley SA, et al. Mesenchymal stem cell inhibition of T-helper 17 cell differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. *Eur J Immunol*. 2011;41:2840-2851.

35. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. *Blood*. 2008;111:1327-1333.

36. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25 (High) forhead box p3+ regulatory T cells. *Clin Exp Immunol*. 2009;156:149-160.

37. Sotiropoulos PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. *Stem Cells*. 2006;24:74-85.

38. Schena F, Gambini C, Gregoria A, et al. Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. *Arthritis Rheum*. 2010;62:2776-2786.

39. Zhang L, Dang RJ, Li H, et al. SOCS1 regulates the immune modulatory properties of mesenchymal stem cells by inhibiting nitric oxide production. *PLoS One*. 2014;9(5):e97256.

40. Rivera-Cruz CM, Shearer JR, Figueiredo Neto M, Figueiredo ML. The immunomodulatory effects of mesenchymal stem cell polarization within the tumor microenvironment niche. *Stem Cells Int*. 2017;2017:4015039.

How to cite this article: Wang Y-H, Huang X-H, Yang Y-M, et al. Mysm1 epigenetically regulates the immunomodulatory function of adipose-derived stem cells in part by targeting mir-150. *J Cell Mol Med*. 2019;23:3737-3746. [https://doi.org/10.1011/jcmm.14281]